Uncategorized

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals counted across the industry for the first half.

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though analysts pledged to wait for more data on safety and tolerability before assessing the drug.

Endoscopy devices restricted from import accounted for about 1% of the company’s consolidated revenue in its latest fiscal year, Olympus said.

The judgment comes in a dispute over a South Carolina policy, but is expected to have sweeping implications nationwide. 

The all-cash buyout, which gives AbbVie access to Capstan Therapeutics’ in vivo edited CAR T therapy for B cell–mediated autoimmune diseases, adds to a growing sense of momentum in M&A, according to BMO Capital Markets.

The agency said it issued the import alerts because it “continues to have concerns related to outstanding Quality System regulation violations by Olympus.”

Patrick Conway, who recently became chief executive of the larger Optum health services division, will replace Dr. Amar Desai as CEO of Optum Health.

Digging into a prespecified analysis for the mid-stage study, INmune Bio identified some clinical and biological benefits of its TNF inhibitor in patients with early Alzheimer’s disease who have at least two biomarkers of inflammation.

The rise of monoclonal antibodies brought back hope for stalling or reversing the devastating neurodegenerative disease. Big Pharma has taken notice with a handful of high-value deals, GlobalData reports.

BMS is letting go of 68 employees in Lawrenceville, New Jersey. The pharma has now cut over 1,000 employees there since April 2024 as part of its cost-cutting measures.